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ABSTRACT
The hepatitis C virus (HCV) E2 envelope glycoprotein is crucial for virus entry into hepatocytes. A conserved region of E2 en-
compassing amino acids 412 to 423 (epitope I) and containing Trp420, a residue critical for virus entry, is recognized by several
broadly neutralizing antibodies. Peptides embodying this epitope I sequence adopt a -hairpin conformation when bound to
neutralizing monoclonal antibodies (MAbs) AP33 and HCV1.We therefore generated newmouseMAbs that were able to bind to
a cyclic peptide containing E2 residues 412 to 422 (C-epitope I) but not to the linear counterpart. These MAbs bound to purified
E2 with affinities of about 50 nM, but they were unable to neutralize virus infection. Structural analysis of the complex between
C-epitope I and one of ourMAbs (C2) showed that the Trp420 side chain is largely buried in the combining site and that the
Asn417 side chain, which is glycosylated in E2 and solvent exposed in other complexes, is slightly buried upon C2 binding. Also,
the orientation of the cyclic peptide in the antibody-combining site is rotated by 180° compared to the orientations of the other
complexes. All these structural features, however, do not explain the lack of neutralization activity. This is instead ascribed to the
high degree of selectivity of the newMAbs for the cyclic epitope and to their inability to interact with the epitope in more flexible
and extended conformations, which recent data suggest play a role in the mechanisms of neutralization escape.
IMPORTANCE
Hepatitis C virus (HCV) remains a major health care burden, affecting almost 3% of the global population. The conserved
epitope comprising residues 412 to 423 of the viral E2 glycoprotein is a valid vaccine candidate because antibodies recognizing
this region exhibit potent neutralizing activity. This epitope adopts a -hairpin conformation when bound to neutralizing
MAbs. We explored the potential of cyclic peptides mimicking this structure to elicit anti-HCV antibodies. MAbs that specifi-
cally recognize a cyclic variant of the epitope bind to soluble E2 with a lower affinity than other blocking antibodies and do not
neutralize virus. The structure of the complex between one suchMAb and the cyclic epitope, together with new structural data
showing the linear peptide bound to neutralizingMAbs in extended conformations, suggests that the epitope displays a confor-
mational flexibility that contributes to neutralization escape. Such features can be of major importance for the design of epitope-
based anti-HCV vaccines.
Hepatitis C virus (HCV), a positive-strand RNA virus belong-ing to the Flaviviridae family, infects nearly 3% of the world’s
population (1). In approximately 70 to 80% of patients, HCV
establishes a chronic infection in the liver that can lead to cirrho-
sis, liver failure, and hepatocellular carcinoma (2). HCV exhibits a
high degree of genetic variability and is classified into seven major
genotypes, each of which contains a large number of related sub-
types (3, 4). This diversity and the high level of intrahost variabil-
ity (quasispecies) contribute to virus persistence in the infected
hosts. The recently developed new therapies have profoundly im-
proved cure rates. However, the higher costs associated with these
new medications are expected to limit their wider utilization (5–
7). As yet, no vaccine against the virus is available.
HCV entry into target cells is believed to be mediated by a
multistep process involving the interplay of the viral envelope gly-
coproteins E1 and E2 and several host cell factors, such as heparan
sulfate, tetraspanin CD81, scavenger receptor class B type I (SR-
BI), and the tight junction (TJ) proteins claudin-1 (CLDN1) and
occludin (8). E1 and E2 are transmembrane proteins with exten-
sive N-linked glycosylation (4 and 11 N-linked glycosylation sites,
respectively) consisting of a large N-terminal ectodomain and a
C-terminal hydrophobic anchor (9). The ectodomain of the E2
protein contains three highly variable regions. Hypervariable re-
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gion 1 (HVR1; residues 384 to 411), located at the N terminus of
E2, plays an important role in HCV entry, antibody binding, and
disease outcome (10). It is now well established that E2 binds
CD81 and SR-BI and that these interactions are a prerequisite for
virus entry (10–13). However, the precise role of the E1-E2 enve-
lope protein complex in HCV entry is still unclear.
The viral glycoprotein E2 is the major target for neutralizing
antibodies. The majority of broadly neutralizing anti-E2 antibod-
ies isolated to date target epitopes spanning the reported CD81
binding sites of E2. Importantly, mouse monoclonal antibody
(MAb) AP33 (14), rat MAb 3/11 (15), and human MAbs HCV1
(16), HC33 (17), and Hu5B3.v3 (18) block the interaction of E2
with CD81 by binding to linear epitopes located within the highly
conserved E2 site encompassing residues 412 to 423, referred to as
antigenic site 412 (AS412) (19) or epitope I (20). Other MAbs
recognize discontinuous E2 epitopes overlapping the CD81 bind-
ing site on E2 and involving residues 395 to 424, 425 to 447, and/or
523 to 540 (21, 22). Residues 412 to 423 have been proposed to be
a potential target for HCV vaccine design (18, 23–26).
Although two independent crystal structures of HCV E2 have
recently been reported (27, 28), they do not provide any structural
data for the region from residues 412 to 423. Indeed, the construct
used by Khan and coworkers (27) spanned E2 residues 456 to 656,
whereas in the structure described by Kong and coworkers (28),
the N-terminal portion encompassing the region from residues
412 to 423 is disordered in the crystal. Interestingly, a peptide
representing this antigenic site adopts a -hairpin conformation
when it is complexed with neutralizing MAb AP33, Hu5B3.v3, or
HCV1, in which Leu413, Gln415, Gly418, and Trp420 are key
residues directly involved in the hydrophobic binding surface (18,
24–26). Since the hairpin-like structure of the antibody-bound
peptides suggests that the region from residues 412 to 423 adopts
a similar conformation in the context of the protein, we designed
and prepared a cyclic variant of the epitope to help the fragment to
assume a hairpin-like structure. The cyclic peptide was used to
immunize mice with a view to isolating novel anti-E2 MAbs. By a
subtractive screening approach, we selected a subset of MAbs rec-
ognizing only the cyclic antigen to explore the possibility of gen-
erating AP33-like antibodies with an improved binding affinity
and neutralization potency. We reasoned that such an approach
might generate antibodies with the potential to more efficiently
capture and lock the epitope in a conformation close to that which
it putatively adopts in the context of the protein in complex with
neutralizing antibodies. However, these MAbs unexpectedly
failed to neutralize virus infection. The results of X-ray studies of
the complex of one of these MAbs with the cyclic peptide, together
with antigen-antibody reactivity data, provide possible explana-
tions for the lack of neutralization activity and offer novel insights
into the design of vaccine candidates targeting the antigenic site
from residues 412 to 423.
MATERIALS AND METHODS
Reagents. TRIzol was purchased from Invitrogen (Carlsbad, CA, USA).
The protein G and A columns and reagents for surface plasmon resonance
(SPR) were purchased from GE Healthcare. Freund’s complete and in-
complete adjuvant and all media, including Dulbecco’s modified Eagle’s
medium (DMEM), Opti-MEM medium, and serum, were purchased
from Gibco (Life Technologies, Italia) and Sigma-Aldrich (Milan, Italy).
RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 1%
penicillin, streptomycin, and glutamine (PSG) was used for maintaining
myeloma cells. RPMI-GM medium contained RPMI 1640 medium with
1% nonessential amino acids. For the fusion of splenocytes and myeloma
cells, we used RPMI 1640 medium supplemented with 15% FBS, 2% hy-
poxanthine-aminopterin-thymidine (HAT), 1% PSG, and 10% hybrido-
ma-enhancing supplement (HES). The same medium lacking HES was
used for hybridoma clone selection. Reagents for peptide synthesis were
from Novabiochem (Laufelfingen, Switzerland), Inbios (Naples, Italy),
and GL Biochem (Shanghai, People’s Republic of China). Solvents for
peptide synthesis and purification were from Romil (Dublin, Ireland).
Other reagents were from Sigma-Aldrich (Milan, Italy). Keyhole limpet
hemocyanin (KLH) was from Pierce-Thermo Fisher (Milan, Italy). The
broadly neutralizing mouse MAb AP33 has been described previously (14,
29). It was generated following immunization of BALB/c mice with a
mammalian cell-expressed recombinant secretory form of the HCV ge-
notype 1a strain Gla E1E2 lacking their respective transmembrane do-
mains (30). Soluble E2 (sE2), comprising the region from amino acids 384
to 661 of genotype 1a strain H77 (GenBank accession no. AF009606) was
expressed by infecting High Five insect cells with a recombinant baculo-
virus, and the protein secreted into the medium was purified by Ni-nitri-
lotriacetic acid chromatography.
Peptide design, synthesis, and purification. Peptides were prepared
under standard conditions of 9-fluorenylmethoxy carbonyl solid-phase
synthesis (31). A cyclic peptide corresponding to the region from residues
412 to 422 of E2 (sequence, QLINTNGSWHI) was designed to facilitate
the adoption of a hairpin-like conformation by the linear epitope. The
structures of the complexes of the linear peptides corresponding to
epitope 412-422 with MAbs AP33, Hu5B3.v3, and HCV1 (24–26) were
used as a guide in the design. The peptide was generated by replacing
Ile411 and Asn423 of E2 with two cysteines, which were then oxidized to
form a disulfide bridge (Fig. 1A). Two lysine residues were added at the N
terminus to allow conjugation to KLH and to bovine serum albumin
(BSA) via glutaraldehyde (amine-to-amine cross-linking). Here this pep-
tide is named C-epitope I. The linear variant (here named L-epitope I)
used in the experiments as a control was obtained by alkylation of the
cysteine thiols. Alanine-mutated variants of C-epitope I were designed
and prepared under the same conditions described above to investigate
the contribution of specific residues to recognition by antibodies. To
overcome the structural similarity of alanine with some of the native res-
idues, we replaced the dyad Gly417-Ser418 with glutamic acids in peptide
mutant III. After synthesis and purification, peptides were cyclized as
reported elsewhere (32). To suppress cysteine reactivity, the linear peptide
was methylated with methyl iodide as reported previously (33). Methyl-
ation was chosen as the modification introducing the minimum structural
change within the molecule.
CD. The purified cyclic peptide was characterized by circular dichro-
ism (CD) using a Jasco J-710 spectropolarimeter (Jasco Corp.) equipped
with a Peltier temperature control system and a 110-QS quartz cuvette
with a 1.0-cm path length. The spectra of peptide solutions at 0.1 mM in
10 mM phosphate buffer, pH 7.0, were collected using the following set-
tings: wavelength range, 190 to 280 nm; scanning speed, 20 nm/min; data
pitch, 0.2 nm; bandwidth, 1 nm; and response time, 4 s. At least five
independent readings of the spectra were averaged and smoothed.
Immunogen preparation. One milligram of C-epitope I was conju-
gated with 3.0 mg of carrier protein (KLH or BSA) in 2.0 ml of 20 mM
phosphate buffer (pH 7.0) containing 0.2% (vol/vol) glutaraldehyde by
stirring the mixture for 3 h. One milliliter of 1 M glycine in water was
added to block the reaction, and then the solutions were extensively dia-
lyzed against phosphate-buffered saline (PBS; pH 7.4) before being lyoph-
ilized. The amount of peptide-protein conjugate was determined using a
Bio-Rad kit (Bio-Rad, Milan, Italy). The same procedure was used to
prepare glutaraldehyde-self-conjugated BSA (BSA2). BSA2 was used as a
control in enzyme-linked immunosorbent assays (ELISAs) to exclude
clones producing antibodies potentially recognizing the amine-cross-
linked glutaraldehyde (34).
Immunization of mice and generation and purification of MAbs.
BALB/c mice were housed and handled according to institutional guide-
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lines (project identification code 2013/0038120, approved by the Ethical
Animal Care and Use Committee of the University of Naples Federico II;
date of approval, 24 April 2013). Four 5-week-old BALB/c mice (The
Jackson Laboratory) were immunized with 100 g of KLH-conjugated
peptide emulsified with complete Freund’s adjuvant. Four independent
injections were carried out subcutaneously with 25 l immunogen. Be-
fore immunization, 250-l blood samples were taken from the caudal
vein of each mouse and used as the preimmune control (time zero sam-
ples). Mice were boosted with the same amount of immunogen in incom-
plete Freund’s adjuvant at day 30 after the first immunization. Blood
samples were taken from the caudal vein (250l) before every subsequent
boosting and tested by ELISA to monitor the antibody titer. A final anti-
gen boost was administered intravenously to mice showing the highest
antibody titer 20 days before they were sacrificed and splenectomized, as
described below.
Cells harvested from the spleens of sacrificed animals were fused with
myeloma SP2/0 cells (ATCC) at a ratio of 5:1 in RPMI-GM containing
polyethylene glycol (PEG) 1300-1600 (Hybri-Max; Sigma-Aldrich, Milan,
Italy) and 7.5% dimethyl sulfoxide (Sigma-Aldrich, Milan, Italy) as de-
scribed previously (35). The fused hybridoma cells were resuspended in
30 ml of selection medium consisting of RPMI-GM medium containing
PEG 1300-1600, 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin,
100 M hypoxanthine, 16 M thymidine, and 400 nM aminopterin
(RPMI-HAT; Sigma-Aldrich, Milan, Italy). The cell suspension was dis-
pensed into 96-well plates and incubated at 37°C in a 5% CO2 atmosphere
with periodic replenishment with fresh selection medium. After 12 to 14
days, the cell medium was screened by ELISA for binding to C-epitope I
and to its linear analogue. Hybridomas secreting antibodies with strong
reactivity with C-epitope I (but not L-epitope I) were recloned twice by
limiting dilution, and their reactivity was reconfirmed by ELISA. Sub-
cloned hybridoma cells were cultured in Opti-MEM medium containing
10% FBS, gradually adapted to serum-free cell culture medium, and then
transferred to bioreactors (Integra Biosciences AG, Chur, Switzerland) for
large-scale antibody production. The antibodies were purified to homo-
geneity by protein G affinity chromatography followed by gel filtration.
Antibodies were characterized by SDS-PAGE, analytical size-exclusion
chromatography, and Western blotting. The immunoreactivity of puri-
fied antibodies with antigen was determined by ELISA, as described
below.
Fab fragment generation and purification. Briefly, Fab fragments
were prepared by papain digestion of purified IgGs. The reaction, moni-
tored by SDS-PAGE, was optimized in 20 mM sodium phosphate and 10
mM EDTA (pH 7.0) buffer using papain at a 1:100 (wt/wt) ratio (Sigma-
Aldrich, Milan, Italy) for 3 h at 37°C. The Fc portion was removed using a
HiTrap protein G column (GE Healthcare, Milan, Italy), and then the Fab
fragment was further purified by gel filtration on a Sephadex 75 column
(GE Healthcare, Milan, Italy) in PBS or 25 mM Tris-HCl, 100 mM NaCl,
pH 7.5. The concentration and purity of the antibodies and Fab fragments
were estimated by determination of the absorbance at 280 nm using a
NanoDrop 2000 spectrophotometer, SDS-PAGE, and size-exclusion
high-performance liquid chromatography.
ELISAs. Titrations of antibody in mouse serum and screening of hy-
bridoma supernatants were performed by ELISA as described elsewhere
(36). Hybridomas were screened for their ability to secrete MAbs specific
for the cyclic antigen. For this purpose, supernatants were tested by coat-
ing plates with both BSA-conjugated C-epitope I and BSA-conjugated
FIG 1 Selection of MAbs specifically binding to the cyclic variant of epitope I. (A) Primary structure of the C-epitope I peptide representing the HCV E2 region
from residues 412 to 422. The peptide was C-terminally amidated, N-terminally acetylated, and cyclized using two cysteines introduced at either end of the native
sequence (underlined). (B) ELISA screening of hybridoma supernatants. C-epitope I and L-epitope I were coated onto microtiter plates at 0.5g/ml. Hybridoma
supernatants were added, and bound antibodies were detected with an HRP-conjugated anti-mouse immunoglobulin antibody. Trastuzumab was used as a
negative control (NC) and was used at the same concentration as the test MAbs. (C) Dose-dependent binding of purified MAbs C1 to C7 to C-epitope I. The
MAbs did not bind to L-epitope I or BSA2 (glutaraldehyde-self-conjugated BSA); only the negative binding data for MAb C2 are shown. (D) Binding of MAb
AP33 to L- and C-epitope I peptides. Abs, absorbance.
MAbs against Cyclic E2 Epitope 412-422
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L-epitope I. Also, BSA2 was used as a control to exclude clones producing
antibodies recognizing the BSA-linked glutaraldehyde. Positive clones
were stabilized by 3 sequential rounds of limiting dilution passages in
96-well plates. Following incubation for 2 weeks at 37°C under 5% CO2,
the supernatant from each well was again tested for the presence of anti-
bodies against the peptide antigen. Hybridomas secreting antibody at the
highest titer were further subjected to 3 rounds of limiting dilution clon-
ing. Finally, the antibodies secreted by selected hybridomas were purified
and tested by ELISA for reactivity to the free C-epitope I and its linear
variant. Briefly, the wells of ELISA plates (MaxiSorp; Nunc) were coated
with the appropriate peptide at 0.5g/ml in PBS by incubation overnight
at 4°C. The wells were blocked with BSA and then washed with PBS-
Tween 20 as described above. Antigen-coated wells were incubated with
0.5 g/ml of appropriate antibodies at 37°C for 60 min, washed as de-
scribed above, and then further incubated with horseradish peroxidase
(HRP)-conjugated anti-mouse IgG (1:1,000; Bio-Rad) at 37°C for 60 min.
After washing, the bound antibody was detected by adding peroxidase
substrate solution (prepared by dissolving o-phenylenediamine dihydro-
chloride at 0.4 mg/ml in 0.1 M citric acid and 0.2 M Na2HPO4 buffer [pH
4.8] and adding 0.2 l/ml of 30% H2O2). Following incubation at room
temperature in the dark, the reaction was stopped with a 2.5 M H2SO4
solution, and the optical density at 492 nm was determined using a mi-
croplate reader (BioTek, Winooski, VT, USA). Specificity was assessed
using an unrelated monoclonal antibody (trastuzumab; Genentech) as a
negative control (NC) and MAb AP33 as a positive control. The negative
and positive controls were used at the same concentration as the test
MAbs.
An ELISA to detect MAb binding to mammalian cell-expressed sE2,
full-length (FL) E2, and the E1E2 glycoprotein was performed essentially
as described previously (14, 37). Briefly, HEK293T cells were cotrans-
fected with plasmids containing the appropriate sequence, and the ex-
pressed glycoproteins present in the clarified lysates of these cells were
captured on Galanthus nivalis agglutinin (GNA)-coated Immulon II en-
zyme immunoassay (EIA) plates (Thermolab Systems). Anti-E2 MAbs
were added, and bound glycoproteins were detected with an anti-mouse
immunoglobulin G-horseradish peroxidase (Sigma, United Kingdom)
and 3,3,5,5-tetramethylbenzidine (TMB; Sigma, United Kingdom) sub-
strate. Absorbance values at 450 nm were determined. Assays for the
screening of the clones were performed at least twice in quadruplicate.
Data are reported as the average of the results from all experiments and
replicates  standard deviation (SD). Assays for MAb binding to pep-
tides and recombinant proteins were performed at least twice. Data are
reported as the average of the results from all experiments and repli-
cates  SD.
Sequencingof antibodyvariable regions and isotypedetermination.
To clone the Ig heavy (H)-chain and light (L)-chain variable-region genes
encoding a subset of the anti-E2 MAbs, total RNA from hybridoma cells
was first used to generate cDNA libraries by reverse transcription reac-
tions with a SuperScript III first-strand kit (Invitrogen) using random
hexamers. The IgG Fab fragments corresponding to the antigen-binding
variable regions were then amplified by PCR using a set of primers specific
for mouse Ig heavy and light chains. The nucleotide sequences of the PCR
products were determined, and their amino acid sequences were deduced
using the program Translate from the ExPASy proteomic server. The iso-
types of the MAbs were determined using a monoclonal antibody isotyp-
ing kit (IsoStrip; Pierce, Rockford, IL, USA) according to the manufactur-
er’s instructions.
SPR analysis. All SPR analyses were performed on a Biacore 3000
instrument from GE Healthcare, using CM5 sensor chips and the HBS
buffer certified for use with this instrument (20 mM HEPES, 0.15 M NaCl,
pH 7.2, 0.005% polysorbate 20), at 25°C. Immobilization was carried out
by means of the canonical amine-coupling chemistry using the surface
immobilization wizard procedure operating at 5 l/min. Channels were
activated with a mixture of 1-ethyl-3-(3-dimethylaminopropyl)-carbodi-
imide and N-hydroxysuccinimide for 7 min; then, the ligand, which had
been appropriately diluted in the preselected sodium acetate buffer, was
coupled until a typical level of 500 to 600 response units (RU) was
achieved. The remaining active ester groups were blocked with 1 M etha-
nolamine HCl, pH 8.5. Measurements of SPR binding to L-epitope, C-
epitope I, and the alanine-mutated variants were carried out by immobi-
lizing each antibody or Fabs on the CM5 sensor chips. Immobilization of
the antibodies, including AP33, was efficiently performed at 5.0 g/ml in
10 mM sodium acetate, pH 4.5, achieving immobilization levels of about
500 to 600 RU in every case. The same procedure was applied to prepare
an sE2-functionalized sensor chip. An IgG1 isotype-matched antibody
was used as a negative control at a concentration of 5.0 M. For epitope
mapping, the Fab fragment of the C2 antibody (Fab C2) at 5.0g/ml in 10
mM sodium acetate, pH 4.5, was directly immobilized onto the CM5
sensor chip (immobilization level, about 500 to 600 RU). An underiva-
tized surface was prepared on every sensor chip and used as a blank con-
trol. All analyses were carried out at a flow rate of 20 l/min, and a con-
stant volume of 60l of protein or peptide solution appropriately diluted
in the HBS running buffer was injected.
For every analysis, experimental sensorgrams were aligned, the blank
signal was subtracted, and the sensorgrams were overlapped. All mathe-
matical manipulations and fitting of the data were performed using
BIAevaluation (version 4.1) software (GE Healthcare). All experimen-
tal data gave optimal fittings when they were processed by assuming a
1:1 Langmuir binding interaction.
HCVcc neutralization assays. Cell culture-infectious HCV (HCVcc)
was produced by electroporation of Huh7 human hepatoma cells with
viral genomic RNA that was generated by in vitro transcription using
plasmid pUC-JFH1 or pUC-JFH1-N417T as the template as described
previously (38, 39). Virus neutralization assays were performed using
Huh7-J20 reporter cells, and virus infectivity levels were determined by a
secreted alkaline phosphatase (SEAP) reporter assay, as described previ-
ously (40). Briefly, Huh7-J20 cells were plated out at a density of 5 103
per well in a 96-well plate. Virus was preincubated with the test antibody
at 37°C for 1 h, prior to infection of the cells at a multiplicity of infection
of 0.1. At 3 h postinfection, the inoculum was replaced with fresh DMEM.
At 72 h postinfection, the SEAP reporter activity (which correlates directly
with the virus infectivity level) in the medium of infected cells was deter-
mined as described previously (40).
Crystallization and diffraction data collection. Trials of the crystal-
lization of the complex consisting of Fab C2 and the peptide were set up at
293 K using the hanging-drop vapor diffusion method. The peptide and
the Fab were previously mixed at a molar ratio of 4:1. Preliminary screen-
ings of the crystallization conditions were carried out using commercially
available sparse-matrix kits (Crystal Screen I/II and Index kits; Hampton
Research) (41). These screenings yielded microcrystals that were opti-
mized by fine-tuning of the protein and precipitant concentrations. Crys-
tals suitable for crystallographic investigations were obtained using a Fab
concentration of 5.0 mg/ml and 0.2 M ammonium sulfate and 25%
(wt/vol) PEG 3350 in a buffer containing 0.1 M bis-Tris, pH 5.5.
Diffraction data were collected in-house at 100 K using a Rigaku Mi-
cromax 007 HF generator that produces Cu K radiation and that is
equipped with a Saturn944 charge-coupled-device detector. Data were
collected at 100 K by adding to the precipitating solution a solution of 20%
(vol/vol) ethylene glycol as a cryoprotectant. The data set was scaled and
merged using the HKL2000 program package (42). Although two angles
of the unit cell were numerically close to 90°, the crystals of the complex
were triclinic. Indeed, all attempts to process the data at a higher symme-
try yielded very high Rmerge values. The analysis of the Matthews coeffi-
cient (Vm) value of this crystal suggests the presence of two molecules in
the asymmetric unit.
Crystallographic refinement. The structure of the complex was
solved by molecular replacement using phaser crystallographic software
(43). Starting models for the light and the heavy chains were selected by
looking for structures in the Protein Data Bank (PDB) with the highest
sequence identities with the sequences of the chains of our Fab. Using this
Sandomenico et al.
3748 jvi.asm.org April 2016 Volume 90 Number 7Journal of Virology
 o
n
 M
arch 31, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
MAbs against Cyclic E2 Epitope 412-422
April 2016 Volume 90 Number 7 jvi.asm.org 3749Journal of Virology
 o
n
 M
arch 31, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
approach, the starting models for the heavy and light chains were ex-
tracted from the structures with PDB accession numbers 2VL5 (identity,
82%) and 3DGG (identity, 94%), respectively. Taking into account the
variability of the relative orientation of the constant and variable regions,
both the heavy and the light chains were fragmented by considering the
individual Fab domains. Therefore, since the asymmetric unit contains
two independent molecules, an ensemble of eight individual fragments
constituted the starting structures in the molecular replacement search.
The application of this procedure provided a straightforward solution.
This model was used for automatic rebuilding, which was carried out
using the ARP-wARP model-building tool (44). Crystallographic
refinement was carried out against 95% of the measured data using the
ccp4i program suite. The remaining 5% of the observed data, which was
randomly selected, was used for Rfree calculations to monitor the progress
of refinement. Noncrystallographic restraints were applied in the Refmac
macromolecular refinement program (45) with medium restraints for the
main chain atoms and loose restraints for side chain atoms. Manual
modeling was performed using the Coot tool (46). Water molecules were
incorporated into the structure in several rounds of successive
refinements.
MDstudies. In order to gain insights into the intrinsic conformational
properties of the cyclic peptide, a molecular dynamics (MD) simulation
was conducted using the structure of the peptide detected in the complex
with Fab C2 as the starting model. The molecular dynamics simulation
was performed using the GROMACS software package (version 4.5.5)
(47), the AMBER99sb force field, and TIP4P as the water model. The
peptide was immersed in a cubic box of 4.50 by 4.50 by 4.50 nm3 contain-
ing 2,933 water molecules. The simulation was run with periodic bound-
ary conditions. The temperature and pressure of the systems were stabi-
lized at 300 K and 1 atm, respectively. Energies were minimized by fixing
the protein atoms, and then the simulation was run without restraints.
The time scale of the simulation was 250 ns with a time step of 0.002
ps. The particle mesh Ewald (PME) method (grid spacing, 0.12 nm)
was used to calculate the electrostatic interactions. A cutoff of 10 Å was
applied to treat Lennard-Jones interactions. Bond lengths were con-
strained using the Linear Constraint Solver (LINCS) algorithm. Tra-
jectories were checked to assess the quality of the simulation using
GROMACS routines. H-bond interactions were identified on the basis
of the cutoffs for the hydrogen donor-acceptor angle (30°) and the
donor-acceptor distance (3.5 Å) by using GROMACS utilities (47).
Protein structure accession number. The coordinates of the model
and the experimental structure factors of the complex have been depos-
ited in PDB under accession number 5EOC.
RESULTS
Production and selection of MAbs against C-epitope I. Hybrid-
oma cell supernatants were directly screened against both
C-epitope I and its linear variant, L-epitope I, conjugated to BSA.
Hybridomas secreting antibodies able to specifically recognize the
cyclic peptide were selected for further studies. This screening
strategy led to the selection of seven different hybridoma clones,
and these were renamed C1 to C7 (Fig. 1B). BSA2 was used in the
subsequent tests to exclude antibodies binding to glutaraldehyde-
cross-linked BSA. These data were confirmed in binding ELISAs
where the free, unconjugated peptides were coated on the plate
surface. The selected MAbs bound to C-epitope I in a dose-depen-
dent fashion (Fig. 1C) but not to L-epitope I or the BSA2 control
(Fig. 1C). As expected, an unrelated IgG1 isotype-matched MAb,
used as a negative control (NC), did not recognize either peptide
(Fig. 1B). MAb AP33, used as a positive control, bound to both the
cyclic and the linear peptides (Fig. 1D). A more detailed charac-
terization of peptide binding to all antibodies was performed by
SPR (see below). All selected MAbs were of the IgG1 isotype with
kappa light chains.
Evaluation of affinity of MAb C1 to C7 binding to C-epitope
I. Binding analyses were performed by SPR with the purified an-
tibodies immobilized on distinct channels of CM5 sensor chips.
SPR dose-response binding assays confirmed that only the cycl-
ized peptide bound the MAbs with a very high affinity (Fig. 2A to
G and Table 1), while no or very poor interactions were observed
with the linear variant (tested at the highest concentration of 10
M; Fig. 2H). The cyclic peptide bound all the immobilized MAbs
with similar association kinetics. The dissociations were instead
much slower for MAbs C6 and C7, which exhibited KD (equilib-
rium dissociation constant) values of about 0.9 nM and 0.7 nM,
respectively (Table 1). The other MAbs showed KDs ranging from
12.7 nM to 44.2 nM. MAb AP33, raised against a recombinant
FIG 2 (A to G) Overlay of sensorgrams showing the binding of C-epitope I at concentrations of between 6.5 nM and 10 M to MAbs C1 (A), C2 (B), C3 (C),
C4 (D), C5 (E), C6 (F), and C7 (G) immobilized on Biacore CM5 sensor chips. (H) Overlay of sensorgrams obtained following the injection of L-epitope I at the
highest concentration of 10M onto the 7 MAbs immobilized on Biacore CM5 sensor chips. (I and J) Overlay of sensorgrams showing the binding of C-epitope
I (I) and L-epitope I (J) to MAb AP33 immobilized on Biacore CM5 sensor chips. Dose-response assays were carried out at the indicated concentrations. All
experiments were carried out at 25°C and a constant flow rate of 20 l/min using HBS as the running buffer. The values of the binding parameters are reported
in Table 1.
TABLE 1 Affinity of antibodies to cyclic and linear epitope 412-422a
MAb
C-epitope I L-epitope I
Ka (1/M · s) Kd (1/s) KD (M) Ka (1/M · s) Kd (1/s) KD (M)
C1 4.84 105 1.20 102 2.48 108 NB
C2 4.07 105 1.23 102 3.03 108 NB
C3 3.21 105 1.01 102 3.14 108 NB
C4 2.82 105 1.25 102 4.42 108 NB
C5 4.34 105 5.52 103 1.27 108 NB
C6 3.59 105 3.22 104 8.97 1010 NB
C7 3.56 105 2.44 104 6.86 1010 NB
AP33 1.21 104 8.62 104 7.11 108 9.99 105 5.34 104 5.35 1010
a Association and dissociation rates and dissociation constants were obtained by SPR for the binding of C-epitope I and L-epitope to MAbs C1 to C7 and AP33. Data were analyzed
using BIAevaluation (version 4.2) software. Ka, association constant; Kd, dissociation constant; NB, no binding.
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soluble form of E1E2 (30), had a 150-fold higher affinity to the
linear peptide than to the cyclic one (KDs 	 0.5 nM and 71 nM,
respectively) (Fig. 2I and J and Table 1).
Binding of MAbs to recombinant sE2 protein. We next eval-
uated the ability of antibodies to recognize recombinant soluble
E2 (sE2) (the relative purity of this protein is shown in Fig. 3H).
For this purpose, dose-dependent binding assays were carried out
on an sE2-functionalized CM5 sensor chip. The binding of AP33
was observed at concentrations ranging from 0.125 nM to 1 nM,
while the interaction with anti-C-epitope I antibodies was ob-
served at MAb concentrations ranging from 100 nM to 1M (Fig.
3A to F). In line with these observations, SPR kinetics and affinity
parameters, summarized in Table 2, showed that AP33 binds sE2
with a considerably higher affinity (KD	 0.142 nM) than anti-C-
epitope I MAbs, which, with the exception of C7, exhibited KD
values of about 50 nM. As expected, no binding to sE2 was de-
FIG 3 (A to G) Overlay of sensorgrams showing the dose-dependent binding of MAbs C2, C3, C4, C6, and C7 (A to E, respectively) and MAb AP33 (F) to sE2
recombinant protein immobilized on Biacore sensor chips. No interaction was detected using an IgG1 isotype at a concentration of 5 M (G). All experiments
were carried out at 25°C and a constant flow rate of 20l/min using HBS as the running buffer. The values of the binding parameters are reported in Table 2. (H)
SDS-PAGE analysis (12% bisacrylamide) of purified sE2 used for SPR binding studies. Lane M, Precision Plus protein standards (10 to 250 kDa; Bio-Rad); lane
1, 2 g of purified sE2 under reducing conditions. Proteins were visualized by the use of Bio-Safe Coomassie blue stain.
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tected using an isotype-matched unrelated IgG1 even at concen-
trations as high as 5 M (Fig. 3G).
Collectively, the SPR data indicate that anti-C-epitope I MAbs
are able to recognize the recombinant soluble E2 protein, al-
though their affinities are significantly lower than their affinities to
the C-epitope I peptide and the affinity exhibited by AP33. It is
worth noting that AP33 bound to sE2 more efficiently than it did
to either the C-epitope I peptide (KD, about 71 nM; Table 1) or the
linear L-epitope I peptide (KD, about 0.5 nM; Table 1). We wished
to test whether MAbs could bind not only to sE2 but also to the
full-length (FL) E2 protein and the E1E2 heterodimer. Transient
transfection of HEK293T cells was used to produce sE2, FL E2, and
E1E2. Proteins from cell extracts were captured onto GNA-coated
ELISA plates. On addition of anti-C-epitope I MAbs C2, C3, C4,
C5, and C7 at 10 g/ml, a weak binding signal was observed with
C2 only, while no binding was observed with the other MAbs (Fig.
4). In contrast, MAb AP33 at 0.02 g/ml gave a strong signal with
all forms of the glycoprotein (Fig. 4).
We next tested whether the MAbs were capable of neutraliza-
tion of retroviral pseudoparticles bearing HCV glycoproteins
(HCVpp) and HCVcc. We found that, unlike MAb AP33, all anti-
C-epitope I MAbs (used at 50 and 100 g/ml, that is, 335 and 670
nM, respectively) failed to neutralize HCVpp bearing E1E2 de-
rived from HCV genotype 1a strain H77 (data not shown). Simi-
larly, these MAbs were also unable to neutralize infection of
Huh-7 cells with the HCVcc genotype 2a strain JFH-1 (data not
shown and Fig. 5). Collectively, these data are in agreement with
the lack of sE2 binding exhibited by anti-cyclic peptide MAbs,
although in consideration of the concentration used in the neu-
tralization tests and the KDs measured by SPR, they do not fully
explain the complete absence of activity. Biacore binding mea-
surements between sE2 and the Fab fragments of both C2 and
AP33 showed that both MAbs displayed an average reduction of
affinity of 5-fold when only one antibody arm was used (Table 2),
a result suggesting that both antibodies exhibited an avidity effect.
Crystal structure of Fab C2 in complex with C-epitope I. To
gain insights into the structural basis of the limited affinity of these
MAbs for sE2 and the lack of neutralization activity, we performed
crystallographic analyses of Fab complexes with the C-epitope I
peptide. Although we were able to obtain crystals or microcrystals
of all the Fabs bound to the C-epitope I peptide, only the Fab
C2-peptide complex was suitable for crystallography. The struc-
ture of this complex was determined to a 1.98-Å resolution. The
triclinic crystals used for the crystallographic investigations con-
tained two independent copies of the complex. The structures of
these two crystal mates were very similar. Indeed, the root mean
square deviation (RMSD) computed on the C- atoms was 0.58 Å.
Therefore, the structural feature of molecule A (Fig. 6A) corre-
sponding to the heavy (H) and light (L) chains was analyzed fur-
TABLE 2 Affinity of antibodies to sE2a
MAb or fragment Ka (1/M · s) Kd (1/s) KD (M)
C2 1.88 104 8.48 104 49.8 109
C3 3.24 104 7.35 104 41.6 109
C4 1.54 104 5.38 104 44.6 109
C5 2.23 104 7.31 104 46.8 109
C7 3.08 103 2.57 104 83.4 109
AP33 6.49 105 6.40 105 0.142 109
Fab C2 1.28 104 4.63 103 301 109
Fab AP33 2.30 105 1.47 104 0.72 109
IgG1 isotype control NB
a Association and dissociation rates and dissociation constants were obtained by SPR
for the binding of MAbs C2, C3, C4, C5, C7, and AP33 and unrelated mouse IgG1 to
sE2. The binding of the Fab fragments of C2 and AP33 to immobilized sE2 was
measured to assess the avidity effects exhibited by the full antibodies. Data were
analyzed using BIAevaluation (version 4.2) software. Ka, association constant; Kd,
dissociation constant; NB, no binding.
FIG 4 Binding of MAbs to envelope glycoproteins in ELISA. HEK293T cell
lysates containing sE2, FL E2, and E1E2 were incubated on GNA-coated wells,
followed by addition of MAb AP33 (0.02g/ml) or MABs C2 to C5 and C7 (10
g/ml). The bound antibodies were detected using HRP-conjugated anti-
mouse IgG.
FIG 5 Neutralization of wild-type and N417T mutant HCVcc by MAbs AP33
and C2. Wild-type (WT) HCVcc strain JFH1 (A) or HCVcc carrying the
N417T mutation (B) was incubated with a range of concentrations of MAb
AP33 or C2 prior to infection of Huh7-J20 cells. At 72 h postinfection, the
activity of the reporter SEAP secreted into the cell medium was measured, and
the infectivity levels were plotted as the percent infectivity relative to that of a
no-antibody control.
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ther. The Fab is composed of the canonical four immunoglobulin
subunits. The elbow angles for the two Fab molecules in the asym-
metric units are 129° and 131°. These values fall in the range ob-
served for kappa Fab structures (48). The complementarity-deter-
mining region (CDR) loops of Fab C2 are also similar to those
observed in canonical structures (49). Since the early stages of the
refinement of the complex, the inspection of the electron density
maps clearly indicated the presence of the peptide in a cleft formed
by the variable regions of the light and heavy chains. As shown in
Fig. 6B, the electron density is well defined for all residues of the
peptide, including the two cysteine residues that form the disul-
fide bridge that closes the loop. The peptide adopts a -hairpin
structure that is stabilized by five hydrogen bonds, four of which
involve the main chain atoms and one of which involves the side
chains. Two backbone H bonds are formed by the nitrogen and
the carbonyl of Gln412 with the carbonyl and the nitrogen of
Ile422, respectively. A similar pair of bonds is formed by Ile414
and Trp420. The network of intrapeptide H bonds is completed by
the one formed by the side chains of Trp420 (atom N-ε1) and
Thr416 (atom O-
1) (Fig. 6C).
Peptide binding by Fab C2 relies on hydrophobic interactions
and the H bonds established at the antibody-combining site (Fig.
6D and E). Both the heavy and the light chains of C2 contribute to
the binding. The surface areas buried upon peptide binding are
353 Å2 and 195 Å2 for the light and the heavy chains, respectively.
The interactions of the light chain with the peptide involve CDRs
light-chain 1 (L1) and L3. In line with other complexes of Fabs
with peptides, no interactions are established by CDR L2. On the
other hand, all three H-chain CDRs (CDRs H1 to H3) establish
interactions with the peptide. The main hydrophobic interactions
are established by Tyr36 (CDR L1), Ile95 (CDR L3), and Trp33
(CDR H1) with the nonpolar residues of the peptide (Trp420 and
Ile422). Most of the H-bonding interactions involve charged side
chains of the Fab. Indeed, the Arg59 (CDR H2) and Asp103 (CDR
H3) side chains of the heavy chain bind Asn417 and Trp420 of the
peptide, respectively. Moreover, the side chains of Arg96 and
Arg100 of CDR L3 bind the carbonyl groups of the main chains of
Asn415 and Thr416, respectively. The ensemble of these intermo-
lecular H bonds is completed by the one formed by the side chain
of Ser32 (CDR L1) and the carbonyl group of Ile422. Crystallo-
graphic and stereochemical statistics for the final models are sum-
marized in Table 3.
Molecular dynamic and circular dichroism studies. The in-
trinsic conformational properties of the cyclic peptide were ana-
lyzed by MD studies. These studies were conducted using the con-
formation of the peptide observed in the complex with Fab C2 as
the starting model. The analysis of the trajectory structure clearly
indicates that the peptide undergoes a significant conformational
FIG 6 Structure of Fab C2 in complex with the C-epitope I peptide. (A) Overview of the C-epitope I peptide bound in the Fab C2 combining site. The peptide
carbon atoms are ramp colored from the N terminus (blue) to the C terminus (red) through green. (B) 2Fo  Fc electron density map of the peptide region
contoured at 1.0 . (C) Backbone intrapeptide H bonds. (D and E) H-bond (D) and hydrophobic (E) interactions at the peptide-Fab C2 interface.
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transition during the MD simulation. Indeed, as shown in Fig. 7A,
the RMSDs indicate that the trajectory structures present signifi-
cant variations from the structure of the starting crystallographic
model. A similar behavior is highlighted by the analysis of the
gyration radius of the simulation structures (Fig. 7B). The analysis
of the gyration radius also indicates that the peptide frequently
assumes structures that are more compact than the elongated
-hairpin motif observed for the peptide in complex with the
antibody. Interestingly, these compact structures occasionally
evolve into -hairpin states resembling the crystallographic one
(at approximately 140 ns, as shown in Fig. 7A). These findings
indicate (i) that the cyclic peptide is intrinsically endowed with a
significant level of flexibility and (ii) that the conformation de-
tected in the complex with Fab C2 is among those conformations
intrinsically accessible to the peptide.
The intrinsic flexibility of the C2 peptide was confirmed by a
circular dichroism analysis performed in aqueous buffer (see Ma-
terials and Methods for details). Indeed, as shown in Fig. 7C, the
CD spectrum of the peptide is suggestive of a very limited content
of regular structure.
To gain deeper insights into the structural features of the
conformational ensemble of the cyclic peptide, we compared
the trajectory structures with the conformation adopted by the
linear variant when complexed with other Fabs. Not surpris-
ingly, when the trajectory structures were compared to the
structure of the linear peptide adopting the -hairpin motif, as
in the complex with AP33, the trends were rather similar to
those observed for the cyclic peptide (Fig. 7A and D). We also
searched the simulation ensemble for structures showing the
highest similarity with the conformation adopted by the linear
variant in complex with AP33. The trajectory structures with
the closest similarity presented RMSD values against this vari-
ant of 1.1 Å. Interestingly, the RMSD displayed by the confor-
mation adopted by the cyclic peptide in the Fab C2 complex
against the same peptide was larger (1.76 Å). However, al-
though the trajectory structure was closer to that of the peptide
bound to AP33, none of them perfectly reproduced it. As ex-
pected, the deviations of the trajectory structures from the
elongated conformations of the peptides in complex with the
Fabs of HC33.1 and 3/11 were much larger (data not shown).
This is an obvious consequence of the restraints imposed by the
disulfide bridge that impede the cyclic peptide from the adop-
tion of highly extended conformations.
C-epitope I mapping using Fab C2. To further investigate
which peptide residues were mostly involved in the binding with
the antibodies, we designed and prepared a panel of alanine-mu-
tated cyclic peptides (Table 4). This study was carried out by SPR
dose-response binding assays on a sensor chip functionalized with
the purified Fab fragment of C2. All peptides were tested at con-
centrations ranging from 125 nM to 5 M. As shown in Table 4,
we found that Fab C2 bound the wild-type C-epitope I peptide
with aKD similar to that exhibited by the whole antibody (30.3 nM
and 32.7 nM, respectively). When we tested the peptides bearing
mutations across residues 411 to 418, we observed that the KD for
peptide mutant II, where the Asn-Thr-Asn amino acids were re-
placed with alanines, was substantially similar to that for the wild
type, that is, 14.8 nM for mutant II and 32.7 nM for the unmodi-
fied peptide. With mutants I and III, the affinity was greatly re-
duced (Table 4), whereas with mutant IV, bearing mutations on
residues 420 to 422 (Trp-His-Ile), the binding was abolished. The
data overall suggested that the triplet Trp420, His421, and Ile422 is
crucial for antibody recognition. These results are in keeping with
the crystallographic findings and provide quantitative informa-
tion on the role played by specific residues of C-epitope I in Fab
recognition.
Neutralization of HCVcc mutant N417T by C2. Our struc-
tural data reveal that the N417 side chain is partially buried upon
Fab C2 binding (Fig. 6D). Since residue N417 is glycosylated in the
native protein, we hypothesized that N417 glycosylation could be
an important factor in E2 recognition by MAb C2. To further
address this issue, we used a virus neutralization assay to evaluate
the ability of MAb C2 to recognize an E2 variant carrying the
mutation N417T, which abolishes this glycosylation site. In this
mutant, the glycosylation site is shifted to N415, whose side chain
is fully exposed in the structure of the complex between Fab C2
and the cyclic peptide (Fig. 6D). This glycan shift has been pro-
posed to render E2 resistant to recognition by anti-epitope I
MAbs, such as AP33 (18). As shown in Fig. 5A and B, MAb C2
failed to neutralize N417T HCVcc as well as the wild-type virus,
while, as expected, MAb AP33 efficiently neutralized the wild-type
virus but not the N417T mutant (18). This observation indicates
that the inability of MAb C2 to recognize HCVcc is not dependent
on the glycosylation status of N417.
DISCUSSION
The elevated costs associated with current antiviral therapies
against hepatitis C and the high disease prevalence necessitate the
urgent development of alternative therapeutic approaches. As for
many other viral diseases, a vaccine would be the most obvious
and a less expensive option. However, the high genetic variability
of the virus is a major barrier that has so far prevented the gener-
TABLE 3 Data collection and refinement statistics
Parametera Value(s) for the peptideb
Data collection statistics
Space group P1
Unit cell dimensions
a, b, c (Å) 54.97, 56.19, 77.15
, , 
 (°) 90.34, 90.18, 94.98
Resolution range (Å) 25.0–1.98
No. of molecules in the asymmetric unit 2
No. of unique observations 59,746
Multiplicity 2.9 (1.9)
Completeness (%) 93.0 (81.7)
Rmerge 0.077 (0.476)
I/(I) 15.9 (1.7)
Refinement statistics
Resolution range (Å) 15.0–19.8
Rfactor/Rfree
c 0.224/0.267
No. of protein/peptide atoms 13,092
No. of water molecules 510
RMSD from ideal structure
Bond length (Å) 0.0020
Bond angle (°) 1.30
a Rmerge 	 hkli|Ii(hkl)I(hkl)|/hkliIi(hkl), where Ii(hkl) is the intensity of an
observation andI(hkl) is the mean value for its unique reflection; summations are
over all reflections. Rfactor 	 h|Fo(h) Fc(h)|/hFo(h), where Fo and Fc are the
observed and calculated structure-factor amplitudes, respectively.
b Values in parentheses refer to the 2.05- to 1.98-Å-resolution shell.
c Rfree was calculated with 5% of the data excluded from the refinement.
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ation of effective anti-HCV vaccines. Several studies have indi-
cated that the HCV surface glycoprotein E2 is a major target for
neutralizing antibodies. However, they are generally isolate spe-
cific and do not recognize E2 proteins from other HCV genotypes,
thus preventing their use as broad-spectrum neutralizing re-
agents. The conserved region from residues 412 to 422 of E2, en-
compassing Trp420, a key residue for HCV recognition by the
human receptor CD81 (9, 11), is recognized by several neutraliz-
ing antibodies (13–17). Despite the crucial role that the residues of
this epitope play in HCV entry, no information on the conforma-
tion(s) that this region adopts in the context of the E2 protein is
available. Structural studies on complexes of the E2 peptide from
residues 412 to 423 with three neutralizing MAbs have shown a
tendency of this fragment to adopt a -hairpin conformation (18,
24–26). In this framework, to gain insights into epitope 412-422
conformational preferences, we generated and characterized a set
of MAbs that selectively recognize a conformationally restrained
cyclic variant of this epitope but not its linear counterpart. Bind-
FIG 7 Intrinsic conformational properties of the cyclic peptide. (A) RMSD values (in angstroms) computed on the C- atoms of the MD trajectory frames
against the starting structure. (B) Time evolution of the radius of gyration (Rg; in angstroms) computed on the C- atoms of the peptide. (C) Far-UV CD
spectrum of the peptide in phosphate buffer at neutral pH. (D) RMSD values (in angstroms) computed on the C- atoms of the trajectory frames against the
conformation of the linear peptide in the complex with AP33 (gray line; PDB accession number 4GAG). RMSD values (in angstroms) of the trajectory structures
versus the starting conformation of the cyclic peptide (black) are shown for comparative purposes.
TABLE 4 Binding affinity of Fab C2 to the epitope I variants used in this studya
Peptide Sequenceb KD (M) Ka (1/s) Kd (1/M · s)
C-epitope I KKCQLINTNGSWHIC 3.27 108 4.77 105 1.56 102
L-epitope I KKC(methyl)QLINTNGSWHIC(methyl) NB 0 0
C-epitope I mutant I KKCAAANTNGSWHIC 4.53 107 1.22 106 5.53 101
C-epitope I mutant II KKCQLIAAAGSWHIC 1.48 108 3.2 103 4.73 105
C-epitope I mutant III KKCQLINTNEEWHIC 4.67 106 1.62 104 7.54 102
C-epitope I mutant IV KKCQLINTNGSAAAC NB 0 0
a Association and dissociation rates and KD values were determined by SPR for the binding of peptides to Fab C2. Data were derived using BIAevaluation (version 4.2) software. Ka,
association constant; Kd, dissociation constant; NB, no binding.
b In C-epitope I and related mutants I to IV, a disulfide bridge connects the two cysteines. In L-epitope I, cysteines are methylated. Methylation is the minimum molecular
modification required to block reactive thiols. C-epitope I mutants I, II, and IV were designed and prepared so that native residues were replace with alanines. In mutant III, glycine
and serine were mutated to glutamic acid because alanines are too similar to glycine and serine.
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ing assays demonstrated that such MAbs were able to bind the
soluble E2 protein with KDs of about 50 nM. This finding holds an
interesting implication. Considering that the MAbs are unable to
recognize the linear peptide representing the sequence of epitope
I, their ability to bind E2 suggests that the protein context has an
impact on the epitope structure, likely shifting its conformation
toward bent states. However, the affinity for E2 exhibited by these
MAbs is significantly lower (approximately 500-fold) than that
exhibited by the neutralizing MAb AP33, and this feature largely
contributes to the lack of activity of the new antibodies.
A crystallographic analysis of the complex between the Fab
fragment of the C2 MAb and the cyclic peptide was undertaken to
unravel the basis of the reduced affinity of the MAbs for the E2
protein and of the consequent inability to neutralize either
HCVpp or HCVcc. A comparison of the crystal structure of the
C-epitope I–Fab C2 complex with the structure of the linear pep-
tide bound to the Fab fragment of hu5B3.v3, AP33, or HCV1 (18,
24–26) shows both analogies and differences. First, in all of these
complexes, the peptide adopts a -hairpin conformation stabi-
lized by H bonds established with main chain atoms. Moreover,
these peptide-Fab complexes feature a similar buried surface area
(250 Å2), with an important contribution to intermolecular in-
teractions being provided by the side chain of Trp420 (Fig. 6D and
E) (18, 24–26). These observations indicate that the C2 MAb,
despite its inability to neutralize virus infection, shares with
hu5B3.v3, AP33, and HCV1 two important features related to the
overall peptide conformation and to the tight binding to the
Trp420 side chain.
A deeper comparison of these complexes underlines, however,
some distinct features in the recognition of the cyclic peptide by
C2. In particular, the binding of C-epitope I by Fab C2 appears to
be rotated by 180° compared to the orientations of the other com-
plexes (Fig. 8A to D). This leads to differences in the interacting
surfaces between the linear and cyclic variant in the complex with
their MAbs (Fig. 9). In particular, residues such as Leu413 and
Asn415, which interact with AP33 and HCV1, are fully exposed in
the C2 complex. On the other hand, the side chain of Asn417,
which is glycosylated in E2 and exposed to the solvent in the other
FIG 8 Comparison of the conformations adopted by epitope 412-422 peptides in complex with Fabs. (A) A structural alignment of peptides bound to AP33
(blue) and to Fab C2 (magenta) shows similar -hairpin conformations. (B) The crystal structures of Fab C2 (orange; this study) and the Fab of AP33 (purple;
PDB accession number 4GAG) are superimposed and faded out. The peptide carbon atoms are ramp colored from the N terminus (blue) to the C terminus (red)
through green, to show that the two peptides are bound in opposite orientations relative to the Fab fragment. (C) Superimposition of the cyclic peptide (with the
carbon atoms in orange) to the linear peptide in its complex with AP33. (D) The peptide structures in the complexes with Fab C2 (orange) and the Fab of AP33
(purple) are aligned to show how the two antibodies approach the opposite surfaces of the peptide hairpin-like structure.
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complexes, is slightly buried upon C2 binding (Fig. 6D). It is
worth mentioning that the failure of C2 to neutralize variants such
as N417T, which cannot be glycosylated at position 417 (18), sug-
gests that the partial burying of Asn417 does not play a major role
in determining the distinctive behavior of C2.
Finally, there is a slight shift in the residues involved in the
hydrogen bonding patterns of the hairpin in the peptide-C2
complex compared to the residues involved in the other com-
plexes. The previously reported structures show that the hair-
pin is stabilized by H bonds between residues 414 and 421 and
between residues 412 and 423, whereas the conformation of the
cyclic peptide bound to C2 is stabilized by H bonds between
residues 412 and 422 and between residues 414 and 420.
Predictive analyses, carried out using the PEP-FOLD server
(http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP
-FOLD/), suggest that the structure observed for the cyclic pep-
tide in the complex is similar to the conformation intrinsically
accessible to the linear sequence of epitope 412-422. Indeed, the
RMSD values of the cyclic peptide structure against the top two
solutions provided by the PEP-FOLD server are in the range of 1.9
to 2.0 Å (50).
Together, these observations may in principle explain the re-
duced affinity of C2 MAb for E2 and suggest that the lack of neu-
tralization may originate from a combination of a low antibody
affinity and an inappropriate approach to the epitope. Indeed,
despite the analogies with other complexes, the specificities of the
C2 complex to the cyclic variant in terms of peptide H-bond pat-
terns and side chain conformations, as well as in terms of the
relative orientation of the epitope and MAb, may limit the ability
of C2 to recognize E2. This implies that the conformations of the
linear peptides observed in the complexes with HCV1 and AP33
represent a reliable model of the structure of the epitope in the
context of real E2.
In this framework, the absence of a significant neutralizing
effect of the MAbs generated against the cyclic variant is likely due
to the inability of this peptide to fully reproduce the epitope con-
formation of the linear variant observed in the complexes with
AP33 and HCV1, which was supported by our MD analysis. How-
ever, it should be noted that while the manuscript was in prepa-
ration, two novel complexes of neutralizing Fabs of MAbs 3/11
and HC33.1 with the linear epitope were reported (51, 52). Sur-
prisingly, in both of these new complexes, the bound peptides
assumed rather extended conformations that were completely un-
related to those observed in the complexes with AP33 and HCV1.
These new data strongly suggest that epitope 412-422 is, in the
protein context, endowed with a remarkable structural versatility,
a property believed to be an additional mechanism of neutraliza-
tion escape (51, 52). The observation that the epitope conforma-
tion recognized by the Fabs of 3/11 and HC33.1 may differ from
that recognized by the Fabs of AP33 and HCV1 suggests that the
specificities of the conformation of the cyclic peptide recognized
by C2 may not be the only factor responsible for the inactivity of
this MAb.
It is likely that our MAbs, which recognize with high selectivity
a conformationally restrained variant of epitope 412-422, are un-
able to accommodate all of its accessible structural states. In other
words, these MAbs are able to bind only a subpopulation of the
diverse conformational ensemble adopted by epitope 412-422, a
property that reflects the reduced affinity of our MAbs for the E2
protein and their inability to display any significant neutralizing
activity. On the other hand, neutralizing MAbs such as AP33,
which recognize both cyclic and linear variants of epitope 412-
422, have a high affinity for E2 since they are able to capture
different conformational states of this E2 region. These consider-
ations should be taken into account in the selection of HCV-neu-
tralizing MAbs and for the design of new potential vaccines.
In conclusion, our data corroborate the emerging notion that
epitope 412-422 is characterized within the protein context by a
high degree of conformational versatility which likely contributes
to a mechanism of conformation-driven neutralization escape.
Since rigid and flexible regions in a protein are typically charac-
terized by conserved and variable sequences, respectively, further
studies are needed to clarify why and how the E2 epitope 412-422
region combines a structural flexibility with a highly conserved
local sequence.
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FIG 9 Histogram showing the buried area for residues 412 to 422 in different
peptide Fab complexes. 4GAG and 4G6A correspond to the PDB accession
numbers of two independent characterizations of the complex between AP33
and the linear epitope (24, 25). 4DGV is the PDB accession number for the
complex between HCV1 and the linear peptide (26); 5EOC is the PDB
accession number of the structure described in this work (Fab C2).
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